IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.25 CHF | -1.32% |
|
+3.40% | +6.43% |
| 05-21 | Idorsia Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 05-21 | Swiss Stocks Flash Red Amid Economic Data Focus in Europe | MT |
| Sales 2024 * | 135M 148M 11.63B | Sales 2025 * | 261M 286M 22.4B | Capitalization | 408M 447M 35.06B |
|---|---|---|---|---|---|
| Net income 2024 * | -407M -446M -34.97B | Net income 2025 * | -349M -383M -29.99B | EV / Sales 2024 * | 11.8 x |
| Net Debt 2024 * | 1.18B 1.3B 102B | Net Debt 2025 * | 1.33B 1.46B 114B | EV / Sales 2025 * | 6.67 x |
| P/E ratio 2024 * |
-1.53
x | P/E ratio 2025 * |
-2.32
x | Employees | 650 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Idorsia Ltd
More recommendations
More press releases
More news
| 1 day | -1.84% | ||
| 1 week | +3.40% | ||
| Current month | +24.31% | ||
| 1 month | +20.64% | ||
| 3 months | -13.79% | ||
| 6 months | +35.62% | ||
| Current year | +6.43% |
1 week
2.13
2.37
1 month
1.782.39
Current year
1.293.70
1 year
1.299.75
3 years
1.2927.08
5 years
1.2933.88
10 years
1.2933.88
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 31/05/17 |
André Muller
DFI | Director of Finance/CFO | 60 | 31/05/17 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 31/05/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 12/05/20 |
Peter Kellogg
BRD | Director/Board Member | 67 | 11/05/21 |
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 31/05/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 746 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/05/24 | 2.25 | -1.32% | 411 404 |
| 27/05/24 | 2.28 | +6.05% | 249,803 |
| 24/05/24 | 2.15 | -2.63% | 584,148 |
| 23/05/24 | 2.208 | -2.13% | 642,082 |
| 22/05/24 | 2.256 | +3.68% | 394,707 |
Delayed Quote Swiss Exchange, May 28, 2024 at 04:31 pm
More quotes
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
13/06/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.28
CHF
Average target price
1.692
CHF
Spread / Average Target
-25.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.43% | 447M | |
| +9.81% | 118B | |
| +9.99% | 106B | |
| -11.82% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.81% | 15.97B | |
| +6.22% | 14.03B | |
| +14.64% | 11.67B |
- Stock Market
- Equities
- IDIA Stock
